Valuation: Zai Lab Limited

Market Cap 2.06B 1.81B 1.69B 1.55B 2.9B 197B 2.97B 20.01B 7.82B 97.51B 7.72B 7.56B 337B P/E 2026 *
-8.16x
P/E 2027 * -9.74x
Enterprise Value 1.56B 1.37B 1.28B 1.18B 2.2B 150B 2.26B 15.21B 5.95B 74.12B 5.87B 5.74B 256B EV / Sales 2026 *
3.49x
EV / Sales 2027 * 2.84x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week-8.33%
1 month+5.77%
3 months-11.76%
6 months+13.01%
Current year+10.74%
1 week 16.1
Extreme 16.1
18
1 month 15.6
Extreme 15.6
18.1
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
132
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.42%-8.33%-50.60%-42.31% 2.09B
+0.03%+6.79%+24.59%-6.79% 70.73B
+0.28%+3.12%+35.58%+214.73% 54.27B
-4.52%+47.90%+47.90%+47.90% 49.28B
-1.45%+8.85%-53.53%-53.08% 39.94B
+1.76%+5.81%+63.59%-21.11% 30.36B
-2.18%+9.77%+64.26%+101.46% 25.96B
-2.36%-6.16%+66.84%-54.08% 22.14B
+2.01%-2.76%-10.26%+145.08% 19.96B
-2.35%+1.06%+80.35%+142.71% 16.77B
Average -1.24%+2.63%+26.87%+47.45% 36.6B
Weighted average by Cap. -1.12%+3.67%+30.19%+52.52%

Financials

2026 *2027 *
Net sales 448M 393M 367M 337M 631M 42.88B 646M 4.35B 1.7B 21.22B 1.68B 1.64B 73.35B 595M 522M 488M 448M 838M 56.95B 858M 5.78B 2.26B 28.18B 2.23B 2.18B 97.43B
Net income -244M -215M -200M -184M -344M -23.39B -352M -2.37B -929M -11.57B -917M -897M -40B -159M -140M -130M -120M -224M -15.22B -229M -1.55B -604M -7.53B -596M -583M -26.03B
Net Debt -493M -434M -405M -371M -695M -47.27B -713M -4.8B -1.88B -23.39B -1.85B -1.81B -80.86B -371M -326M -305M -280M -523M -35.57B -536M -3.61B -1.41B -17.6B -1.39B -1.36B -60.85B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
29/07/26 EUR 16.10 -2.42%
28/07/26 EUR 16.50 +0.61%
27/07/26 EUR 16.40 -3.53%
24/07/26 EUR 17.00 -3.41%
23/07/26 EUR 17.60 -2.22%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.31USD
Average target price
33.30USD
Spread / Average Target
+81.89%

Quarterly revenue - Rate of surprise